<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973086</url>
  </required_header>
  <id_info>
    <org_study_id>HP/190201/CITRUSLIM/BCMH</org_study_id>
    <nct_id>NCT03973086</nct_id>
  </id_info>
  <brief_title>To Assess the Efficacy of CitruSlim® on Body Composition as Well as Metabolic and Hormonal Factors in Overweight and Obese Individuals</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy of CitruSlim® on Body Composition as Well as Metabolic and Hormonal Factors in Overweight and Obese Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CitruSlim® can promote healthy weight loss by promoting anabolic state during weight loss
      programs, prevent the body from storing fat, reduce appetites and maintain healthy
      cholesterol and blood glucose level during weight loss program.

      This study focuses to prove the efficacy and safety of the product in a population of
      overweight and obese individual.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body fat percent Body Mass Index (kg/m2)</measure>
    <time_frame>16 weeks.</time_frame>
    <description>Assessed using DEXA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Lean Body Mass (g)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed using DEXA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Body Fat (%)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed using DEXA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fat Free Mass (g)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed using DEXA</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Citruslim (Low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Citruslim (High dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Microcrystaline Cellulose- 400mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citruslim- LD</intervention_name>
    <description>Low Dose of 200 mg</description>
    <arm_group_label>Citruslim (Low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citruslim- HD</intervention_name>
    <description>High Dose of 400 mg</description>
    <arm_group_label>Citruslim (High dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (Microcrystalline Cellulose) of 400 mg</description>
    <arm_group_label>Microcrystaline Cellulose- 400mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female participants with the age of ≥18 and ≤ 60 years of age.

          2. BMI of ≥25 - ≤ 35 kg/m2

          3. Waist circumference:India: Men: &gt; 94 cm (37 inches), Women: &gt;80 cm (31.5 inches) USA:
             Men: &gt; 102 cm (40 inches), Women: &gt;89 cm (35 inches)

          4. Triglycerides &gt;150 mg/dL

          5. Blood pressure: Systolic: ≥130 mm Hg and/or Diastolic: ≥85 mm Hg

          6. Fasting blood glucose ≥ 100 mg/ dl

          7. Low HDL level: Men: &lt; 40 mg/dL, Women: &lt; 50 mg/dL

          8. Ready to give voluntary, written, informed consent to participate in the study.

        Exclusion Criteria:

        Participants meeting any of the following criteria will be excluded from the trial:

          1. Current smoker.

          2. Inability to walk independently.

          3. Presence of unstable, acutely symptomatic, or life-limiting illness.

          4. Neurological conditions causing functional or cognitive impairments

          5. Unwillingness or inability to be randomized to one of three intervention groups.

          6. Bilateral hip replacements.

          7. Exposure to any non-registered drug product within 3 months prior to the screening
             visit.

          8. Unable/unwillingness to complete study specific diaries (digital/paper-based).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zubair Ansari, M.Pharm</last_name>
    <phone>022 42172328</phone>
    <phone_ext>328</phone_ext>
    <email>zubair@vediclifesciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Reveal</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Mayper</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

